Login to Your Account



Newron’s Parkinson’s drug draws an FDA request for more data

By Michael Fitzhugh
Staff Writer

Wednesday, March 30, 2016

With an FDA complete response letter in hand, Newron Pharmaceuticals SpA is on the hook for providing the agency with a clinical evaluation of the potential abuse liability and dependence or withdrawal effects of its Parkinson’s disease candidate, Xadago.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription